|
AU2003259296A1
(en)
|
2002-07-30 |
2004-02-16 |
University Of Virginia Patent Foundation |
Compounds active in spinigosine 1-phosphate signaling
|
|
WO2005041899A2
(en)
|
2003-11-03 |
2005-05-12 |
University Of Virginia Patent Foundation |
Orally available sphingosine 1-phosphate receptor agonists and antagonists
|
|
CA2547198A1
(en)
*
|
2003-12-17 |
2005-06-30 |
Merck & Co., Inc. |
(3,4-disubstituted)propanoic carboxylates as s1p (edg) receptor agonists
|
|
EP1772145B1
(en)
|
2004-07-16 |
2011-03-23 |
Kyorin Pharmaceutical Co., Ltd. |
Method of effectively using medicine and method concerning prevention of side effect
|
|
WO2006010379A1
(en)
|
2004-07-29 |
2006-02-02 |
Actelion Pharmaceuticals Ltd. |
Novel thiophene derivatives as immunosuppressive agents
|
|
EP1798226A4
(en)
|
2004-08-04 |
2009-06-17 |
Taisho Pharmaceutical Co Ltd |
TRAIZOL DERIVATIVE
|
|
JP2008509931A
(ja)
|
2004-08-13 |
2008-04-03 |
プレーシス ファーマスーティカルズ インコーポレイテッド |
スフィンゴシン−1−ホスフェート(s1p)レセプター活性を調節するための方法および組成物
|
|
US20060223866A1
(en)
*
|
2004-08-13 |
2006-10-05 |
Praecis Pharmaceuticals, Inc. |
Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
|
|
ES2615498T3
(es)
*
|
2004-10-12 |
2017-06-07 |
Kyorin Pharmaceutical Co., Ltd. |
Procedimiento para producir hidrocloruro de 2-amino-2-[2-[4-(3-benciloxifeniltio)-2-clorofenil]etil]-1,3-propanodiol
|
|
US7754703B2
(en)
|
2005-02-14 |
2010-07-13 |
University Of Virginia Patent Foundation |
Cycloalkane-containing sphingosine 1-phosphate agonists
|
|
CN101146529B
(zh)
|
2005-03-23 |
2012-08-29 |
埃科特莱茵药品有限公司 |
新颖噻吩衍生物作为鞘氨醇-1-磷酸酯-1受体激动剂
|
|
EP1863787B1
(en)
|
2005-03-23 |
2011-05-25 |
Actelion Pharmaceuticals Ltd. |
Hydogrenated benzo[c]thiophene derivatives as immunomodulators
|
|
AU2006239418A1
(en)
|
2005-04-26 |
2006-11-02 |
Neurosearch A/S |
Novel oxadiazole derivatives and their medical use
|
|
EP1893591A1
(en)
*
|
2005-06-08 |
2008-03-05 |
Novartis AG |
POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS
|
|
KR101297302B1
(ko)
*
|
2005-10-07 |
2013-08-19 |
교린 세이야꾸 가부시키 가이샤 |
2-아미노-1,3-프로판디올 유도체를 유효성분으로 하는간장질환 치료제 및 간장질환 치료방법
|
|
TWI404706B
(zh)
|
2006-01-11 |
2013-08-11 |
Actelion Pharmaceuticals Ltd |
新穎噻吩衍生物
|
|
JP5063615B2
(ja)
|
2006-01-24 |
2012-10-31 |
アクテリオン ファーマシューティカルズ リミテッド |
新規ピリジン誘導体
|
|
GB0601744D0
(en)
*
|
2006-01-27 |
2006-03-08 |
Novartis Ag |
Organic compounds
|
|
EP1986623A2
(en)
|
2006-01-27 |
2008-11-05 |
University Of Virginia Patent Foundation |
Method for treatment of neuropathic pain
|
|
RU2409570C2
(ru)
*
|
2006-02-03 |
2011-01-20 |
Тайсо Фармасьютикал Ко., Лтд. |
Производные триазола
|
|
TWI389683B
(zh)
*
|
2006-02-06 |
2013-03-21 |
Kyorin Seiyaku Kk |
A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
|
|
WO2007091570A1
(ja)
|
2006-02-06 |
2007-08-16 |
Taisho Pharmaceutical Co., Ltd. |
スフィンゴシン-1-リン酸結合阻害物質
|
|
WO2007092638A1
(en)
|
2006-02-09 |
2007-08-16 |
University Of Virginia Patent Foundation |
Bicyclic sphingosine 1-phosphate analogs
|
|
CN101384566A
(zh)
*
|
2006-02-21 |
2009-03-11 |
弗吉尼亚大学专利基金会 |
作为s1p受体激动剂的苯基-环烷基和苯基-杂环衍生物
|
|
EP2003132B1
(en)
|
2006-04-03 |
2014-03-05 |
Astellas Pharma Inc. |
Oxadiazole derivatives as S1P1 agonists
|
|
PL2058317T3
(pl)
|
2006-08-08 |
2014-03-31 |
Kyorin Seiyaku Kk |
Aminowa pochodna estru kwasu fosforowego i modulator receptora S1P zawierający ją jako składnik aktywny
|
|
WO2008018447A1
(en)
|
2006-08-08 |
2008-02-14 |
Kyorin Pharmaceutical Co., Ltd. |
Aminoalcohol derivative and immunosuppressant containing the same as active ingredient
|
|
MY149853A
(en)
|
2006-09-07 |
2013-10-31 |
Actelion Pharmaceuticals Ltd |
Pyridin-4-yl derivatives as immunomodulating agents
|
|
TWI408139B
(zh)
|
2006-09-07 |
2013-09-11 |
Actelion Pharmaceuticals Ltd |
新穎噻吩衍生物
|
|
CL2007002594A1
(es)
|
2006-09-08 |
2008-06-06 |
Actelion Pharmaceuticals Ltd |
Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
|
|
KR20090051774A
(ko)
|
2006-09-21 |
2009-05-22 |
액테리온 파마슈티칼 리미티드 |
페닐 유도체 및 면역조절제로서 이들의 용도
|
|
WO2008064337A2
(en)
|
2006-11-21 |
2008-05-29 |
University Of Virginia Patent Foundation |
Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity
|
|
EP2097397A1
(en)
|
2006-11-21 |
2009-09-09 |
University Of Virginia Patent Foundation |
Tetralin analogs having sphingosine 1-phosphate agonist activity
|
|
EP2099741A2
(en)
|
2006-11-21 |
2009-09-16 |
University Of Virginia Patent Foundation |
Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity
|
|
AU2013201157B2
(en)
*
|
2006-12-21 |
2015-06-11 |
Glaxo Group Limited |
Indole derivatives as s1p1 receptor agonists
|
|
GB0625647D0
(en)
*
|
2006-12-21 |
2007-01-31 |
Glaxo Group Ltd |
Compounds
|
|
JO2701B1
(en)
*
|
2006-12-21 |
2013-03-03 |
جلاكسو جروب ليميتد |
Vehicles
|
|
GB0625648D0
(en)
*
|
2006-12-21 |
2007-01-31 |
Glaxo Group Ltd |
Compounds
|
|
CN100494178C
(zh)
*
|
2007-02-02 |
2009-06-03 |
广东东阳光药业有限公司 |
一种吡啶甲脒及其盐的制备方法
|
|
JP5390404B2
(ja)
*
|
2007-02-16 |
2014-01-15 |
エミスフェアー・テクノロジーズ・インク |
活性薬剤を送達するための環状部分を有する化合物及び組成物
|
|
DK2125797T3
(da)
*
|
2007-03-16 |
2014-02-10 |
Actelion Pharmaceuticals Ltd |
Aminopyridinderivater som s1p1/edg1-receptoragonister
|
|
CA2684385A1
(en)
*
|
2007-04-19 |
2008-10-30 |
Glaxo Group Limited |
Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (s1p) agonists
|
|
AU2008282156B2
(en)
*
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
CN101790517B
(zh)
|
2007-08-01 |
2013-08-21 |
大正制药株式会社 |
抑制s1p1结合的物质
|
|
KR101541558B1
(ko)
*
|
2007-08-17 |
2015-08-03 |
액테리온 파마슈티칼 리미티드 |
S1p1/edg1 수용체 조절제로서의 피리딘 유도체
|
|
CN101815707B
(zh)
*
|
2007-10-04 |
2015-09-02 |
默克雪兰诺有限公司 |
噁二唑二芳基化合物
|
|
CA2696863C
(en)
*
|
2007-10-04 |
2016-10-18 |
Anna Quattropani |
Oxadiazole derivatives
|
|
CA2700917A1
(en)
*
|
2007-11-01 |
2009-05-07 |
Actelion Pharmaceuticals Ltd |
Novel pyrimidine derivatives
|
|
JP5452237B2
(ja)
|
2008-02-07 |
2014-03-26 |
杏林製薬株式会社 |
アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
|
|
WO2009109906A1
(en)
*
|
2008-03-06 |
2009-09-11 |
Actelion Pharmaceuticals Ltd |
Pyridine compounds
|
|
GB0807910D0
(en)
|
2008-04-30 |
2008-06-04 |
Glaxo Group Ltd |
Compounds
|
|
WO2009137342A1
(en)
|
2008-05-08 |
2009-11-12 |
Allergan, Inc. |
Therapeutically useful substituted 1, 7-diphenyl-l, 2, 3, 5, 6, 7-hexahydropyrido [ 3, 2, 1-i j ] quinoline compounds
|
|
WO2009151626A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Arena Pharmaceuticals, Inc. |
Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
|
|
WO2009151621A1
(en)
*
|
2008-06-13 |
2009-12-17 |
Arena Pharmaceuticals, Inc. |
Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists
|
|
CN104311472B9
(zh)
|
2008-07-23 |
2020-03-17 |
艾尼纳制药公司 |
经取代的1,2,3,4-四氢环戊并[b]吲哚-3-基乙酸衍生物
|
|
US8415484B2
(en)
|
2008-08-27 |
2013-04-09 |
Arena Pharmaceuticals, Inc. |
Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
|
|
KR20170015566A
(ko)
|
2008-11-10 |
2017-02-08 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물
|
|
EP2376485B1
(en)
|
2008-12-19 |
2017-12-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazine derivatives useful as inhibitors of atr kinase
|
|
EP2210890A1
(en)
*
|
2009-01-19 |
2010-07-28 |
Almirall, S.A. |
Oxadiazole derivatives as S1P1 receptor agonists
|
|
JP2012515787A
(ja)
*
|
2009-01-23 |
2012-07-12 |
ブリストル−マイヤーズ スクイブ カンパニー |
自己免疫疾患および炎症性疾患の処置におけるs1pアゴニストとしての置換オキサジアゾール誘導体
|
|
US8389509B2
(en)
*
|
2009-01-23 |
2013-03-05 |
Bristol-Myers Squibb Company |
Substituted pyrazole compounds
|
|
JP5753104B2
(ja)
*
|
2009-03-03 |
2015-07-22 |
メルク セローノ ソシエテ アノニム |
S1p1レセプターアゴニストとして有用なオキサゾールピリジン誘導体
|
|
CA2767585C
(en)
*
|
2009-07-16 |
2017-09-26 |
Actelion Pharmaceuticals Ltd |
Pyridin-4-yl derivatives
|
|
US8399451B2
(en)
|
2009-08-07 |
2013-03-19 |
Bristol-Myers Squibb Company |
Heterocyclic compounds
|
|
SG10201500639TA
(en)
|
2010-01-27 |
2015-03-30 |
Arena Pharm Inc |
Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
|
|
EP2542554B1
(en)
|
2010-03-03 |
2015-11-04 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof
|
|
US8247436B2
(en)
|
2010-03-19 |
2012-08-21 |
Novartis Ag |
Pyridine and pyrazine derivative for the treatment of CF
|
|
EP2560969B1
(en)
|
2010-04-23 |
2015-08-12 |
Bristol-Myers Squibb Company |
4-(5-isoxazolyl or 5-pyrrazolyl-1,2,4-oxadiazol-3-yl)-mandelic acid amides as sphingosin-1-phosphate 1 receptor agonists
|
|
KR20130066633A
(ko)
|
2010-05-12 |
2013-06-20 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물
|
|
EP2569286B1
(en)
|
2010-05-12 |
2014-08-20 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
AU2011253021A1
(en)
|
2010-05-12 |
2012-11-29 |
Vertex Pharmaceuticals Incorporated |
2 -aminopyridine derivatives useful as inhibitors of ATR kinase
|
|
EP2568984A1
(en)
|
2010-05-12 |
2013-03-20 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8962631B2
(en)
|
2010-05-12 |
2015-02-24 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
MX2013000103A
(es)
|
2010-06-23 |
2013-06-13 |
Vertex Pharma |
Derivados de pirrolo-pirazina utiles como inhibidores de cinasa art.
|
|
ES2548258T3
(es)
|
2010-09-24 |
2015-10-15 |
Bristol-Myers Squibb Company |
Compuestos de oxadiazol sustituidos y su uso como agonistas de S1P1
|
|
ES2525298T3
(es)
*
|
2010-11-03 |
2014-12-19 |
Bristol-Myers Squibb Company |
Compuestos heterocíclicos como agonistas del S1P1 para el tratamiento de enfermedades autoinmunes y vasculares
|
|
RU2013129483A
(ru)
|
2010-12-03 |
2015-01-10 |
Аллерган, Инк. |
Новые фениловые производные оксадиазола в качестве модуляторов рецептора сфингозин 1-фосфата (s1p)
|
|
EP2646023B1
(en)
|
2010-12-03 |
2015-01-07 |
Allergan, Inc. |
Novel azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
|
|
BR112013013644A2
(pt)
*
|
2010-12-03 |
2016-09-06 |
Allergan Inc |
derivados de oxadiazol como moduladores dos receptores de esfingosina 1-fosfato (s1p)
|
|
FR2968556B1
(fr)
*
|
2010-12-13 |
2013-12-27 |
Centre Nat Rech Scient |
Inhibiteurs des infections a vih et leurs utilisations
|
|
MX350009B
(es)
|
2011-01-19 |
2017-08-23 |
Idorsia Pharmaceuticals Ltd |
Derivados de 2-metoxi-piridin-4-ilo.
|
|
JP2014510151A
(ja)
|
2011-04-05 |
2014-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物
|
|
EP2723746A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
JP2014522818A
(ja)
|
2011-06-22 |
2014-09-08 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
WO2012178123A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
KR102056586B1
(ko)
|
2011-09-30 |
2019-12-18 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 억제제를 이용한 췌장암 및 비소세포 폐암의 치료
|
|
WO2013049720A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
BR112014007721B1
(pt)
|
2011-09-30 |
2022-11-01 |
Vertex Pharmaceuticals Incorporated |
Processos para preparar compostos úteis como inibidores de atr quinase
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2751099B1
(en)
|
2011-09-30 |
2017-06-14 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071093A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
WO2013071094A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2776421A1
(en)
|
2011-11-09 |
2014-09-17 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071090A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
US8841449B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2015515478A
(ja)
|
2012-04-05 |
2015-05-28 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な化合物及びそれらの併用療法
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8735433B1
(en)
|
2012-11-14 |
2014-05-27 |
Allergan, Inc. |
Aryl oxadiazole derivatives as sphingosine 1-phosphate (S1P) receptor modulators
|
|
BR112015012454B1
(pt)
|
2012-12-07 |
2022-07-05 |
Vertex Pharmaceuticals Incorporated |
Compostos inibidores de atr quinase, seu uso e composição farmacêutica compreendendo os mesmos
|
|
US8871755B2
(en)
|
2013-02-12 |
2014-10-28 |
Allergan, Inc. |
Alkene azetidine derivatives as sphingosine 1-phosphate (S1P) receptor modulators
|
|
WO2014143240A1
(en)
|
2013-03-15 |
2014-09-18 |
Vertex Pharmaceuticals Incorporated |
Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
|
|
ES2768678T3
(es)
|
2013-12-06 |
2020-06-23 |
Vertex Pharma |
Compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]pirazolo[1,5-a]pirimidin-3-carboxamida útil como inhibidor de la ATR quinasa, su preparación, diferentes formas sólidas y derivados radiomarcados de las mismas
|
|
ES2777608T3
(es)
|
2014-06-05 |
2020-08-05 |
Vertex Pharma |
Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
|
|
KR20170016498A
(ko)
|
2014-06-17 |
2017-02-13 |
버텍스 파마슈티칼스 인코포레이티드 |
Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법
|
|
ES2995737T3
(en)
|
2015-01-06 |
2025-02-11 |
Arena Pharm Inc |
Compound for use in treating conditions related to the s1p1 receptor
|
|
KR102220848B1
(ko)
|
2015-05-20 |
2021-02-26 |
이도르시아 파마슈티컬스 리미티드 |
화합물 (s)-3-{4-[5-(2-시클로펜틸-6-메톡시-피리딘-4-일)-[1,2,4]옥사디아졸-3-일]-2-에틸-6-메틸-페녹시}-프로판-1,2-디올의 결정형
|
|
MA42807A
(fr)
|
2015-06-22 |
2018-07-25 |
Arena Pharm Inc |
Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
|
|
KR102678021B1
(ko)
|
2015-09-30 |
2024-06-26 |
버텍스 파마슈티칼스 인코포레이티드 |
Dna 손상제와 병용되는, atr 저해제를 포함하는 암 치료용 약제학적 조성물
|
|
CA3053416A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations
|
|
WO2018151873A1
(en)
|
2017-02-16 |
2018-08-23 |
Arena Pharmaceuticals, Inc. |
Compounds and methods for treatment of primary biliary cholangitis
|
|
CN108178759B
(zh)
*
|
2018-01-05 |
2020-06-09 |
上海瑞纷医药科技有限责任公司 |
一种α-肾上腺素受体拮抗剂的合成方法
|
|
EP3801459B1
(en)
|
2018-06-06 |
2024-08-07 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the s1p1 receptor
|
|
WO2020051378A1
(en)
|
2018-09-06 |
2020-03-12 |
Arena Pharmaceuticals, Inc. |
Compounds useful in the treatment of autoimmune and inflammatory disorders
|
|
WO2025151705A1
(en)
*
|
2024-01-10 |
2025-07-17 |
Vrise Therapeutics, Inc. |
Novel inhibitors of dna damage repair pathway
|